An orally available drug enters the brain and interferes with signaling of orexin neuropeptides-providing a potential treatment for sleep disorders and possibly addiction (pages 150-155).
greatly improved skeletal muscle regeneration.
The authors next asked what would happen if they blocked the AT1 receptor with losartan. AT1 blockade had previously been shown to antagonize TGF-β signaling in other tissues 4 . Losartan improved muscle morphology, reduced TGF-β signaling and enhanced regeneration in muscles of the Marfan syndrome mouse model.
Might elevated TGF-β signaling also limit regeneration in muscular dystrophies? The authors addressed this question by exploring the mdx mouse model for DMD, which results from mutations in the cytoskeletal protein dystrophin 6 . Previous studies had shown that TGF-β inhibition reduced fibrosis in mdx muscles, but regeneration per se was not studied, although muscles from mdx mice display a mild regeneration defect 7, 8 .
Cohn et al. found that muscles from mdx mice expressed elevated levels of proteins induced by TGF-β signaling, and they also displayed elevated levels of thrombo spondin-1, which activates latent TGF-β in response to signaling through the AT1 receptor ( Fig. 1 and refs. 9,10 ). These biochemical abnormalities were largely reversed with losartan treatment. Treatment with either neutralizing antibodies to TGF-β or losartan also greatly improved muscle regeneration. Long-term treatment with losartan improved muscle histopathology, decreased fibrosis and increased both absolute myofiber number and force generation, even though individual muscle fibers were still fragile and susceptible to necrosis.
The beneficial effects of losartan treatment appear to derive from a decrease in fibrosis coupled with a boost in regenerative capacity. Thus, losartan was able to lower TGF-β signaling and increase muscle morphology and strength in two unrelated models of myopathy, raising the possibility that inhibition of regeneration might be a common theme that affects the progression of multiple myopathies.
The results obtained with the Marfan syndrome mouse argue strongly for testing losartan in patients. The use of losartan in severe forms of muscular dystrophy, however, may need to be approached cautiously. A peculiar feature of DMD is that patients are born healthy and without obvious muscle weakness. However, at around age 5 patients develop progressive muscle weakness associated with a gradual loss of muscle fibers and a parallel increase in fibrosis 6 . One theory has been that the dystrophic muscles function fairly normally as long as regeneration is maintained, but that after years of continual muscle degeneration the repair processes are no longer able to maintain muscle mass.
What is not clear, however, is why regeneration ultimately fails in DMD. TGF-β inhibition of satellite cell activation appears to be one mechanism, but there is another that may be more problematic. Regeneration may fail in part due to exhaustion of the satellite cell pool via proliferative senescence following years of continuous muscle repair 11 . In this scenario, losartan treatment might initially slow the decline in muscle function while accelerating the onset of satellite cell senescence, leading to an exacerbation of muscle pathology in older patients.
Testing this hypotheses could be done by using the dog model of DMD, which displays a more progressive loss of muscle mass than does the mdx mouse 12 .
Regardless of the long-term consequences, the fact that losartan is already widely used in the clinic could enable patients to enjoy an increase in mobility and quality of life while awaiting the development of more challenging treatments designed to correct the primary cause of the disorder.
In the meantime, losartan treatment provides a promising approach to alleviating pathology in Marfan syndrome and other myopathies. The drug should also provide new insights to stimulate additional study of the basic pathological mechanisms underlying various disorders of muscle.
The Roman god Janus displays two faces, one looking back and the other toward what lies ahead. Like Janus, we can look back over the last several years and appreciate how much we have learned about the roles of the orexin neuropeptides in the regulation of wakefulness and sleep, the control of body weight and metabolism, and the regulation of motivation and addiction 1 . Looking ahead, we may soon see the application of these discoveries to clinical practice.
In this issue, Brisbare-Roch et al. describe a novel, orally administered drug that produces sleepiness through selective blockade of orexin signaling 2 . Quite possibly, this drug may be clinically useful for promoting sleep, and, by modulating reward circuits, it may become a novel treatment for drug addiction.
Orexin-A and orexin-B (also known as hypocretin-1 and hypocretin-2) are produced by a cluster of neurons in the posterior lateral hypothalamus (Fig. 1) . The orexin neurons help promote and sustain wakefulness by providing excitatory drive to a variety of brain regions that govern arousal and alertness. In addition, orexins are essential regulators of REM sleep, the sleep stage characterized by vivid dreams and paralysis of nearly all muscles.
The importance of orexin is especiallyclear in people with narcolepsy. These individuals have an acquired loss of the orexinproducing neurons, which results in chronic sleepiness and intrusions into wakefulness of REM sleep-like phenomena, including dream-like hallucinations and cataplexy (emotionally triggered episodes of muscle weakness similar to the paralysis of REM sleep [3] [4] [5] ). Brisbare-Roch et al. found that a new orexin antagonist (ACT-078573) selectively blocked both orexin receptors (OX 1 and OX 2 ) at nanomolar concentrations, but it had little affinity for other G proteincoupled receptors 2 . The drug was orally active and rapidly entered the brain. When given to rats during their active period, it increased REM and non-REM sleep for at least 12 hours, and dogs treated with it spent more time in a sleeping posture as shown by video analysis. In a small number of people treated with the drug during the day, many felt sleepy, and, when permitted to nap, they fell asleep quickly. Many sedatives can produce sensations of drunkenness or unsteadiness, but these and other side effects were uncommon with this orexin antagonist.
The sleepiness produced by this drug affirms that orexins promote wakefulness in people, just as suggested by much animal research. More importantly, this drug may have several useful clinical applications.
At first glance one might think that an orexin antagonist could be a useful addition to the current selection of drugs for insomnia. Many of the medications now used to promote sleep, such as benzodiazepines and the newer agents such as zolpidem, enhance signaling through GABA A receptors. Other choices include GABA B agonists, antihistamines and melatonin agonists, yet patients sometimes find the current drugs ineffective or the side effects intolerable.
The early findings with this orexin antagonist show that it can promote sleep, but not everyone with sleep problems is likely to find it effective. The authors show this compound was moderately effective at promoting sleep when given to rats and dogs during the active period, but, in striking contrast to traditional sedatives, it had no effect when given during their rest periods. Orexins are released during active wakefulness but not during the sleep period [6] [7] [8] , so this drug may not benefit most people with insomnia. On the other hand, it may be very effective in shift workers or people with jet lag trying to sleep when their biological clock is signaling wakefulness.
In mice, rats, dogs and people, disrupted orexin signaling causes narcolepsy with cataplexy [3] [4] [5] [9] [10] [11] . Although the new orexin antagonist thoroughly blocks orexin signaling and produces sleepiness, surprisingly it does not appear to produce cataplexy. In part, this may be a consequence of the authors' definition of cataplexy that differs from prior studies in narcoleptic rodents (in which the EEG pattern during cataplexy resembles that seen in REM sleep; see refs. 10,12). But even when this drug was given to people, no obvious cataplexy occurred.
This lack of cataplexy could be due to the experimental conditions: cataplexy in people is often triggered by laughter, and heartfelt mirth is very difficult to elicit in the lab. It is also possible that cataplexy only develops with chronic loss of orexin signaling, so it will be important to assess carefully whether cataplexy develops after weeks of treatment with the antagonist.
Another possible use of this orexin antagonist is suggested by new work indicating that orexin neurons play an essential role in modulating reward pathways 13 . Rewarding stimuli such as cocaine, morphine and food trigger release of dopamine from the mesolimbic dopamine projections, and excessive activity in this pathway can cause addiction. Orexins enhance signaling in this reward network, and mice lacking orexins not only eat less but also show much less addictive behavior with morphine or amphetamines 14, 15 . Thus, by reducing activity in reward pathways, an orexin antagonist might be useful in the treatment of obesity or drug addiction by reducing food or drug craving and the risk of relapse. Still, this may not be as simple as it appears: rats and dogs treated with the orexin antagonist were sluggish and moved less around their cages. It is unclear whether they moved less because they were sleepy or because their reward pathways were inactivated (reducing their motivation to move).
Hence, an orexin antagonist may help people troubled by substance abuse only if it can be given at a dose that dampens activity in reward pathways without producing too much sedation or a general lack of motivation.
A wealth of animal research has demonstrated the importance of orexins in promoting arousal, regulating reward and driving appetite, and this new antagonist provides an opportunity to better understand the functions of orexins in human behavior. The early findings with this drug are encouraging, yet much more needs to be done before it can be brought to the clinic. First, it will be essential to define which patients are most likely to benefit from the sedating actions of this drug; then, sleep recordings will need to be examined in detail to ensure that acute and chronic use of the antagonist produces good quality Katie Ris sleep without triggering cataplexy when the patients are awake. It may also be worthwhile to test this antagonist as a novel therapy for the treatment of substance abuse. However, like the two faces of Janus, it will be important when evaluating orexin antagonists to be wary of the implications of their other face: reducing the motivation that is the zest of life.
The essence of energy homeostasis is the ability to sense the amounts of circulating nutrients and to adjust metabolic pathways in order to maintain tightly controlled nutrient levels. A vast array of hormones and nutrients impinge on metabolic networks, with the end result being homeostasis. Although numerous studies have deciphered how glucose and other nutrients can directly trigger a metabolic response such as insulin secretion or lipogenic gene expression 1 , little is known about how this is accomplished mechanistically.
Reporting in Nature, Mitro et al. 2 now fill a major gap in our understanding of how glucose is sensed in cells and controls energy metabolism. They show that glucose, the most basic and common energy molecule, is an endogenous ligand and direct activator of the nuclear hormone receptor LXR-known for sensing intermediates in cholesterol metabolism, the oxysterols, and for controlling cholesterol homeostasis. Their study shows how glucose and lipids are sensed through the same protein in order to control the expression of genes linked to nutrient homeostasis (Fig. 1) . This finding has extraordinary implications for understanding the body's ability to maintain energy balance.
In response to high glucose concentrations, there is a concerted shift in metabolism, namely, a lowering of hepatic glucose production and an induction of energy storage through lipogenesis. Insulin has long been thought to be the key hormone that synchronizes this metabolic shift throughout the body-but, after very detailed studies in recent years, it is becoming unclear what the direct effects of insulin actually are. Many metabolic changes once thought to be caused by insulin might only coincide with insulin signaling and may actually have other regulatory stimuli. To a certain extent, even in the absence of insulin signaling the body is capable of responding to fluctuations in glucose and other energy molecules 3 .
Clearly, other pathways sense the energy and nutrient status of cells. Nuclear hormone receptors, for instance, are at the center of a network for metabolic control of transcription. As transcriptional regulators they are unique, because in the presence or absence of ligand they can function as a switch, turning on or off transcription of target genes. The ligands for nuclear receptors tend to be metabolic intermediates in pathways regulated by the receptors; these intermediates perhaps function as sensors for the activity of those pathways. Importantly, nuclear receptors are also great drug targets because of their ability to regulate transcription in response to small molecules and to restore dysregulated metabolic pathways in human diseases; an example is the PPARγ ligand rosiglitazone, used in the treatment of type 2 diabetes.
Among the nuclear receptors, LXR is at the center of glucose and lipid metabolic control. There are two LXR isoforms: LXR-β is ubiquitously expressed, and LXR-α is expressed in metabolically active tissues such as the liver, macrophages and the intestine. LXR functions as a key regulator of fatty acid and cholesterol metabolism; its known targets include genes involved in lipogenesis (genes for SREBP-1c, FAS), cholesterol transport (genes encoding ABCA1, ABCG1) and, interestingly, carbohydrate metabolism (genes for PEPCK, LPK).
Consistent with LXR's role in lipid metabolism, oxysterols are known endogenous ligands 4 . There are also several potent, high-affinity synthetic ligands for LXR. In physiologic studies, the activation of LXR by ligands has many antidiabetic and antiatherogenic effects, shifting metabolism toward energy storage; this shift includes a lowering of glycemia and an increase in lipid show that glucose is a high-affinity ligand for LXR. Thus, LXR acts as dual sensor for glucose and oxysterols. The strength of LXR signaling can fluctuate widely, depending on nutritional states. LXR activates genes in the gluconeogenic/glycolytic, fatty acid synthesis and cholesterol transport pathways in order to control nutrient and energy homeostasis.
